AMENDMENT TO THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of claims:

Claim 1 (currently amended). A method for ~~inhibiting matrix metalloproteinase enzymes in a mammal comprising administering to the mammal an MMP inhibiting~~ treating breast carcinoma, rheumatoid arthritis, osteoarthritis, or heart failure, the method comprising administering to a patient suffering from breast carcinoma, rheumatoid arthritis, osteoarthritis, or heart failure a therapeutically effective amount of a compound of Formula I



I

wherein:

R^1, R^2, and R^3 independently are hydrogen, halo, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyl, C_2-C_6 alkynyl, NO_2, NR^4R^5, CN, or CF_3;

E is independently O or S;

A and B independently are OR^4 or NR^4R^5;

each R^4 and R^5 independently are $(CH_2)_n$ heterocyclyl, $(CH_2)_n$ heteroaryl, or R^4 and R^5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;

n is an integer from 0 to 6;

or a pharmaceutically acceptable salt thereof;

wherein the compound isophthalic acid bis-(1,3-benzodioxol-5-ylmethyl) ester is excluded.

Claim 2 (currently amended). A method for ~~inhibiting matrix metalloproteinase enzymes in a mammal comprising administering to the mammal an MMP inhibiting~~ treating breast carcinoma, rheumatoid arthritis, osteoarthritis, or heart failure, the method comprising administering to a patient suffering from breast carcinoma, rheumatoid arthritis, osteoarthritis, or heart failure a therapeutically effective amount of a compound of Formula II



II

wherein:

R^1, R^2, and R^3 independently are hydrogen, halo, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyl, C_2-C_6 alkynyl, NO_2, NR^4R^5, CN, or CF_3; and

R^4 and R^5 is independently $(CH_2)_n$ heterocyclyl, $(CH_2)_n$ heteroaryl, or R^4 and R^5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;

n is an integer from 0 to 6;

or a pharmaceutically acceptable salt thereof;

wherein the compound isophthalic acid bis-(1,3-benzodioxol-5-ylmethyl) ester is excluded.

Claim 3 (currently amended). A method for ~~inhibiting matrix metalloproteinase enzymes in a mammal comprising administering to the mammal an MMP inhibiting~~ treating breast carcinoma, rheumatoid arthritis, osteoarthritis, or heart failure, the method comprising administering to a patient suffering from breast carcinoma, rheumatoid arthritis, osteoarthritis, or heart failure a therapeutically effective amount of a compound of Formula III



III

wherein:

R^1, R^2, and R^3 independently are hydrogen, halo, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyl, C_2-C_6 alkynyl, NO_2, NR^4R^5, CN, or CF_3;

R^4 and R^5 independently are $(CH_2)_n$ heterocyclyl, $(CH_2)_n$ heteroaryl, or R^4 and R^5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;

n is an integer from 0 to 6;

or a pharmaceutically acceptable salt thereof.

Claim 4 (cancelled).

Claim 5 (currently amended). A method for ~~inhibiting matrix metalloproteinase enzymes in a mammal comprising administering to the mammal an MMP inhibiting~~ treating breast carcinoma, rheumatoid arthritis, osteoarthritis, or heart failure, the method comprising administering to a patient suffering from breast carcinoma, rheumatoid arthritis, osteoarthritis, or heart failure a therapeutically effective amount of a compound of Formula V



V

wherein:

R^1, R^2, and R^3 independently are hydrogen, halo, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyl, C_2-C_6 alkynyl, NO_2, NR^4R^5, CN, or CF_3, and Het is an unsubstituted or substituted heteroaryl group;

R^4 and R^5 independently are $(CH_2)_n$ heterocyclyl, $(CH_2)_n$ heteroaryl, or R^4 and R^5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;

n is an integer from 0 to 6;

or a pharmaceutically acceptable salt thereof;

wherein the compound isophthalic acid bis-(1,3-benzodioxol-5-ylmethyl) ester is excluded.

Claim 6 (currently amended). A method for ~~inhibiting matrix metalloproteinase enzymes in a mammal comprising administering to the mammal an MMP inhibiting~~ treating breast carcinoma, rheumatoid

arthritis, osteoarthritis, or heart failure, the method comprising administering to a patient suffering from breast carcinoma, rheumatoid arthritis, osteoarthritis, or heart failure a therapeutically effective amount of a compound of Formula VI



VI

or a pharmaceutically acceptable salt thereof,

wherein:

R^1, R^2, and R^3 independently are hydrogen, halo, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyl, C_2-C_6 alkynyl, NO_2, NR^4R^5, CN, or CF_3;

R^4 and R^5 independently are $(CH_2)_n$ heterocyclyl, $(CH_2)_n$ heteroaryl, or R^4 and R^5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; and

n is an integer from 0 to 6.

Claim 7 (currently amended). A compound selected from the group consisting of:

Isophthalic acid di-(2,1,3-benzothiadiazol-5-yl) methyl ester;

4-Methoxy-isophthalic acid dipyridin-4-ylmethyl ester;

N,N′-Bis-1,3-benzodioxol-5-ylmethyl-4-methoxy-isophthalamide;

N-1,3-Benzodioxol-5-ylmethyl-N′-furan-2-ylmethyl-isophthalamide;

4-Methoxy-isophthalic acid di-2,1,3-benzothiadiazol-5-ylmethyl ester;

N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-ethoxy-isophthalamide;

N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-ethoxy-isophthalamide;
N1-1,3-Benzodioxol-5-ylmethyl-N3-pyridin-3-ylmethyl-isophthalamide;
N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-isopropoxy-isophthalamide;
4-Amino-N1,N3-bis-1,3-benzodioxol-5-ylmethyl-isophthalamide;
4-Acetylamino-N1,N3-bis-1,3-benzodioxol-5-ylmethyl-isophthalamide;
N1-1,3-Benzodioxol-5-ylmethyl-N3-pyridin-3-ylmethyl-isophthalamide;
N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-ethoxy-isophthalamide;
N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-propoxy-isophthalamide;
N1,N3-Bis-1,3-benzodioxol-5-ylmethyl-4-isopropoxy-isophthalamide;
N1,N3-Bis-2,1,3-benzothiadiazol-5-ylmethyl-4-methoxy-isophthalamide; and
4-Methoxy-isophthalic acid di-2,1,3-benzothiadiazol-5-ylmethyl ester.

Claim 8 (currently amended). A pharmaceutical composition, comprising a compound of ~~Claim 1~~ Claim 18, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, diluent, or excipient.

Claims 9 to 12 (cancelled).

Claim 13 (currently amended). A method for treating breast carcinoma, the method comprising administering to a patient suffering from ~~such a disease~~ breast carcinoma an anticancer effective amount of a compound of ~~Claim 1~~ Claim 18, or a pharmaceutically acceptable salt thereof.

Claim 14 (currently amended). A method for treating ~~a~~ rheumatoid arthritis, the method comprising administering to a patient suffering from ~~such a disease~~ rheumatoid arthritis ~~an~~ a therapeutically effective amount of a compound of ~~Claim 1~~ Claim 18, or a pharmaceutically acceptable salt thereof.

Claim 15 (currently amended). A method for treating ~~a~~ osteoarthritis, the method comprising administering to a patient suffering from ~~such a disease~~ osteoarthritis ~~an~~ a therapeutically effective amount of a compound of ~~Claim 1~~ Claim 18, or a pharmaceutically acceptable salt thereof.

Claim 16 (currently amended). A method for treating ~~a~~ heart failure, the method comprising administering to a patient suffering from ~~such a disease~~ heart failure ~~an~~ a therapeutically effective amount of a compound of ~~Claim 1~~ Claim 18, or a pharmaceutically acceptable salt thereof.

Claim 17 (cancelled).

Claim 18 (new). A compound of Formula III



III

wherein:

R^1, R^2, and R^3 independently are hydrogen, halo, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyl, C_2-C_6 alkynyl, NO_2, NR^4R^5, CN, or CF_3;

R^4 and R^5 independently are $(CH_2)_n$ heterocyclyl, $(CH_2)_n$ heteroaryl, or R^4 and R^5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;

n is an integer from 0 to 6;

or a pharmaceutically acceptable salt thereof.